Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on March 7, 2008, to report a material definitive agreement entered into on March 6, 2008. This agreement is a manufacturing supply agreement between its wholly-owned Irish subsidiary, Gilead Sciences Limited (GSL), and Ampac Fine Chemicals LLC (AFC). The core of the agreement involves GSL committing to purchase minimum quantities of bulk tenofovir disoproxil fumarate from AFC through 2010. This active pharmaceutical ingredient is crucial for Gilead's key HIV medications, including Truvada, Atripla, and Viread. This filing indicates Gilead is securing its supply chain for these important revenue-generating drugs.
Key Highlights
- 1Gilead Sciences Limited (GSL), an Irish subsidiary, entered into a Manufacturing Supply Agreement with Ampac Fine Chemicals LLC (AFC) on March 6, 2008.
- 2The agreement focuses on the supply of bulk tenofovir disoproxil fumarate, a key active pharmaceutical ingredient (API).
- 3GSL is committed to purchasing minimum quantities of this API from AFC through the year 2010.
- 4The tenofovir disoproxil fumarate supplied under this agreement is used in Gilead's significant HIV medications: Truvada®, Atripla®, and Viread®.
- 5This filing signals a strategic move by Gilead to ensure a stable and contracted supply of a critical component for its important drug portfolio.
- 6The agreement covers the period leading up to and including 2010, providing supply chain visibility for these key products.